Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue

Photochemistry and Photobiology

Volumn 89, Issue 3, 2013, Pages 698-708

  Ibsen, Stuart ^a   Zahavy, Eran ^b   Wrasidlo, Wolf ^c   Hayashi, Tomoko ^c   Norton, John ^c   Su, Yongxuan ^d   Adams, Stephen ^d   Esener, Sadik ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; DOXORUBICIN; DRUG DERIVATIVE; PHOTOSENSITIZING AGENT; PRODRUG;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; LIGHT; LUNG TUMOR; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; SYNTHESIS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CYCLODEXTRINS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIGHT; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PRODRUGS; TUMOR BURDEN;

EID: 84876797404     PISSN: 00318655     EISSN: 17511097     Source Type: Journal    
DOI: 10.1111/php.12045     Document Type: Article

References (48)

1. Cvetkoviand, R. S., and, L. J. Scott, (2005) Dexrazoxane: A review of its use for cardio protection during anthracycline chemotherapy. Drugs 65, 1005-1024.
2. Pawan, N. I., and, K. Singal, (1998) Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905.
3. Metzger, M. L., J. S., Dome, (2005) Current therapy for Wilms' tumor. Oncologist 10, 815-826.
4. D'Angio, G. J., (2003) Pre- or post-operative treatment for Wilms tumor? Who, What, When, Where, How, Why-and Which. Med. Pediatr. Oncol. 41, 545-549.
5. Shapiroand, C., and, A. Recht, (2001) Side effects of adjuvant treatment of breast cancer. N. Engl. J. Med. 344, 1997-2008.
6. Demetri, G. D., A. L. Cesne, S. P. Chawla, T. Brodowicz, R. G. Maki, B. A. Bach, D. P. Smethurst, S. Bray, Y.-j. Hei, and, J.-Y. Blay, (2012) First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A phase I/II open-label and double-blind study. Eur. J. Cancer. Online.
7. Olson R. D., P. S. Mushlin, (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J. 4, 3076-3086.
8. Giorgio Minotti, P. M., E. Salvatorelli, G. Cairo, and, L. Gianni, (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229.
9. Ewer, M. S., N. Jaffe, H. Ried, H. A. Zietz, and, R. S. Benjamin, (1998). Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med. Pediatr. Oncol. 31, 512-515.
10. Mertens, A. C., Y. Yasui, J. P. Neglia, J. D. Potter, M. E. N. Jr, K. Ruccione, W. A. Smithson, and, L. L. Robison, (2001). Late mortality experience in five-year survivors of childhood and adolescent cancer: The childhood cancer survivor study. J. Clin. Oncol. 19, 3163-3172.
11. Gabizon, A. A., (2001) Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19, 424-436.
12. R) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 440-449.
13. Cheong, I., X. Huang, C. Bettegowda, L. A., Jr Diaz, K. W. Kinzler, S. Zhou, and, B. Vogelstein, (2006). A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 314, 1308-1311.
14. Moghimi, S. M., A. C. Hunter, and, J. C. Murray, (2001). Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283-318.
15. Wood, B. J., R. T. Poon, J. K. Locklin, M. R. Dreher, M. Eugeni, G. Seidel, S. Dromi, Z. Neeman, M. Kolf, C. D. V. Black, R. Prabhakar, and, S. K. Libutti, (2012). Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J. Vasc. Interv. Radiol. 23, 248-255.
16. Wang, S., S. P. Mahesh, J. Liu, C. Geist, and, V. Zderic, (2012). Focused ultrasound facilitated thermo-chemotherapy for targeted retinoblastoma treatment: A modeling study. Exp. Eye Res. 100, 17-25.
17. Niand, T., and, Baudisch, P., (2009) Disappearing mobile devices, Proceedings of the 22nd annual ACM symposium on User interface software and technology, Association for Computing Machinery, Victoria, British Columbia, Canada, pp. 101-110.
18. Amit, B., U. Zehavi, and, A. Patchornik, (1974). Photosensitive protecting groups of amino sugars and their use in glycoside synthesis. 2-nitrobenzyloxycarbonylamino and 6-nitroveratryloxycarbonylamino derivatives. J. Org. Chem. 39, 192-196.
19. Ibsen, S., E. Zahavy, W. Wrasdilo, M. Berns, M. Chan, and, S. Esener, (2010). A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm. Res. 27, 1848-1860.
20. Miwa, M., M. Ura, M. Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, and, H. Ishitsuka, (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34, 1274-1281.
21. Denny, W. A., (2001). Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36, 577-595.
22. Denny, W. A., (2004). Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. 22, 604-619.
23. Lutz, M. N., F. Tietze, T. Mollers, R. Fischer, K.-H. Glusenkamp, M. F. Rajewsky, and, E. Jahde, (1989). Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: A strategy for tumor-selective activation of cytocidal drugs. Cancer Res. 49, 4179-4184.
24. Martin Brown, W. R. W. J., (2004). Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447.
25. Breistol, H. R. H. K., D. P. Berger, S. P. Langdon, H. H. Fiebig, and, O. Fodstad, (1998). The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. Eur. J. Cancer 34, 1602-1606.
26. Gopin, A., S. Ebner, B. Attali, and, D. Shabat, (2006). Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with PEG via click chemistry. Bioconjugate Chem. 17, 1432-1440.
27. Shamis, M., H. N. Lode, and, D. Shabat, (2004). Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. JACS 126, 1726-1731.
28. Barbara, W. A. W., M. Mueller, and, R. A. Reisfeldt, (1990). Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjugate Chem. 1, 325-330.
29. Park, J., K. Hong, D. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U. Nielsen, J. Marks, D. Moore, D. Papahadjopoulos, and, C. Benz, (2002). Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172-1181.
30. Vaupel, P., F. Kallinowski, and, P. Okunieff, (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 49, 6449-6465.
31. Dominic, R. H. S., A. Scudiere, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, and, M. R. Boyd, (2004). A distinct "side population" of cells with high drug efflux capacity in human tumor cells. PNAS 101, 14228-14233.
32. Fradet, Y., N. Islam, L. Boucher, C. Parent-Vaugeois, and, M. Tardif,. (1987). Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U S A 00, 84.
33. Fradet, Y., N. Islam, L. Boucher, C. Parent-Vaugeois, and, M. Tardif, (1987). Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U S A 84, 7227-7231.
34. Yuanlong Yang, E. J. C., J. A. Koutcher, and, R. R. Alfano, (2001). UV reflectance spectroscopy probes DNA and protein changes in human breast tissues. J. Clin. Laser Med. Surg. 19, 35-39.
35. Sutherland, J., and, K. Griffin, (1981). Absorption spectrum of DNA for wavelengths greater than 300 nm. Radiat. Res. 86, 399-410.
36. Ibsen, S., Y. Su, J. Norton, E. Zahavy, T. Hayashi, S. Adams, W. Wrasidlo, and, S. Esener,.(In submission). Development of a Mass Spectrometry and Tissue Extraction Method to Detect Small Amounts of Photoreleased Doxorubicin in Tumor Tissue. J. Mass Spectromet.
37. Staveren, H. J. V., C. J. M. Moes, J. V. Marie, S. A. Prahl, and, M. J. C. V. Gemert, (1991). Light scattering in Intralipid-1 0% in the wavelength range of 400-1 1 00 nm. Appl. Opt. 30, 4507-4515.
38. Loftssonand, T., and, M. E. Brewster, (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025.
39. Johansen, P. B., (1981). Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother. Pharmacol. 5, 267-270.
40. Dolmans, D. E. J. G. J., D. Fukumura, and, R. K. Jai, (2003). Photodynamic therapy for cancer. Nat. Rev. Cancer 3, 380-387.
41. Hendersonand, B., and, T. Dougherty, (1992). How does photodynamic therapy work? Photochem. Photobiol. 55, 145-157.
42. Quigley, G. J., A. H.-J. Wang, G. Ughetto, G. V. D. Marel, J. H. V. Boom, and, A. Rich, (1980). Molecular structure of an anticancer drug-DNA complex: Daunomycin plus d(CpGpTpApCpG). Proc. Natl. Acad. Sci. U S A 77, 7204-7208.
43. Gewirtz, D. A., (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubici. Biochem. Pharmacol. 57, 727-741.
44. Neoptolemos, J. P., D. D. Stocken, J. A. Dunn, J. Almond, H. G. Beger, P. Pederzoli, C. Bassi, C. Dervenis, L. Fernandez-Cruz, F. Lacaine, J. Buckels, M. Deakin, F. A. Adab, R. Sutton, C. Imrie, I. Ihse, T. Tihanyi, A. Olah, S. Pedrazzoli, D. Spooner, D. J. Kerr, H. Friess, and, M. W. Büchler, (2001). Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. 234, 758-768.
45. Roelcke, U., O. Hausmann, A. Merlo, J. Missimer, R. P. Maguire, P. Freitag, E. W. Radü, R. Weinreich, O. Gratzl, and, K. L. Leenders, (2002). PET imaging drug distribution after intratumoral injection: The case for 124I-iododeoxyuridine in malignant gliomas. J. Nucl. Med. 43, 1444-1451.
46. Currier, M. A., L. C. Adams, Y. Y. Mahller, and, T. P. Cripe, (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene. Ther. 12, 407-416.
47. Fiandaca, M. S., J. R. Forsayeth, P. J. Dickinson, and, K. S. Bankiewicz, (2008). Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5, 123-127.
48. Lammers, T., P. Peschke, R. Kühnlein, V. Subr, K. Ulbrich, P. Huber, W. Hennink, and, G. Stormy, (2006). Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 8, 788-795.